Targets › ESR1
85 programs from 74 companies in 221 trials: 91 Phase 2, 53 Phase 3, 43 Phase 1, 34 Phase 4; Oncology, Genitourinary, Metabolic and endocrine; next expected readout Nov 2026.
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. (UniProt, P03372)
Open in Phaseline: the race on ESR1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of California, San Francisco | Hormone Replacement Therapy (HRT) Estrogen and progestin replacement | ESR1, ESR2, PGR | Phase 4 | Adhesive Capsulitis of the Shoulder | Dec 2026 |
| The Alfred | Bazedoxifene Acetate Selective estrogen receptor modulator (SERM) | ESR1, ESR2 | Phase 4 | Schizophrenia | Dec 2026 |
| Mackay Memorial Hospital | Conjugated equine estrogen (Premarin) Estrogen receptor agonist (vaginal cream formulation) | ESR1, ESR2 | Phase 4 | Effect of Drug | Dec 2026 |
| Insel Gruppe AG, University Hospital Bern | Hormone Replacement Therapy (HRT) Transdermal estradiol and oral micronized progesterone replacement | ESR1, ESR2, PGR | Phase 4 | Insomnia | Jan 2027 |
| University of California, Irvine | Estring Vaginal Product Estradiol released locally from a vaginal ring | ESR1, ESR2 | Phase 4 | Recurrent Urinary Tract Infection | Jun 2027 |
| Andrew Zakhari | Estetrol Estrogen receptor agonist | ESR2, ESR1 | Phase 4 | Ovarian Endometrioma | Jul 2027 |
| University of Southern California | Clomiphene Citrate Estrogen receptor alpha modulator | ESR1 | Phase 4 | Infertility, Female | Jun 2028 |
| Peking Union Medical College Hospital | Femoston 2/10 Estradiol and dydrogesterone hormone replacement therapy | ESR1, PGR | Phase 4 | Functional Hypothalamic Amenorrhea | Jun 2028 |
| Penn State University | Combined Oral Contraceptive (COC) / Apri (Reclipsen) Oral ethinyl estradiol-based contraceptive; estrogen receptor agonist | ESR1, ESR2, PGR | Phase 4 | Other Disorders of Bone Development and Growth | Dec 2028 |
| Gangnam Severance Hospital | Tamoxifen Estrogen receptor alpha modulator | ESR1 | Phase 4 | Breast Cancer | Jan 2031 |
| GE Healthcare | 18F Fluoroestradiol (ESTROTEP) Estrogen receptor imaging agent | ESR1 | Phase 4 | Metastatic Breast Cancer | – |
| Rachel Mejia | Clomiphene Citrate Estrogen receptor alpha modulator | ESR1 | Phase 4 | Polycystic Ovary Syndrome | – |
| Stemline Therapeutics | Elacestrant Estrogen receptor alpha degrader | ESR1 | Phase 3 | Breast Cancer; Metastatic Breast Cancer; Breast Neoplasms; Advanced Breast Cancer … | Nov 2026 |
| Pfizer | CMP 001 6-valent OspA-based Lyme disease vaccine | ESR1, OSPAB | Phase 3 | Lyme Disease; Advanced Malignancies; Lyme Borreliosis; Advanced Breast Cancer … | Dec 2026 |
| Pfizer | vepdegestrant Estrogen receptor degrader (SERD) | ESR1 | Phase 3 | Breast Cancer; Healthy Participants | Dec 2026 |
| Eli Lilly | Imlunestrant (LY3484356) Selective estrogen receptor degrader (SERD) | ESR1 | Phase 3 | Breast Neoplasms; Breast Cancer; Anatomic Stage I Breast Cancer AJCC v8 | Dec 2026 |
| AstraZeneca | Fulvestrant Estrogen receptor alpha antagonist; Estrogen receptor degrader | ESR1 | Phase 3 | Breast Cancer; Locally Advanced or Metastatic Breast Cancer; Estrogen Receptor-positive Breast Cancer; Breast Cancer Metastatic … | Dec 2026 |
| National Cancer Institute (NCI) | Tamoxifen Citrate Estrogen receptor alpha modulator | ESR1 | Phase 3 | Breast Ductal Carcinoma In Situ; Breast Adenocarcinoma; Breast Atypical Hyperplasia; Breast Atypical Ductal Hyperplasia | Jan 2027 |
| Andrea DeCensi | Tamoxifen Estrogen receptor alpha modulator | ESR1 | Phase 3 | Carcinoma, Intraductal, Noninfiltrating; Breast Cancer | Jan 2027 |
| Eurofarma Laboratorios | Estradiol Estrogen receptor alpha agonist | ESR1 | Phase 3 | Acne Vulgaris | Feb 2027 |
| Fudan University | tamoxifen Estrogen receptor alpha modulator | ESR1 | Phase 3 | Ductal Carcinoma In Situ, DCIS; Pancreatic Neoplasms | Feb 2027 |
| LeonaBio | Lasofoxifene Estrogen receptor modulator | ESR2, ESR1 | Phase 3 | Metastatic Breast Cancer | Apr 2027 |
| AstraZeneca | Camizestrant (AZD9833) Estrogen receptor alpha degrader | ESR1 | Phase 3 | Breast Cancer, Early Breast Cancer; ER-Positive HER2-Negative Breast Cancer; Advanced Breast Cancer; Advanced ER-Positive HER2-Negative Breast Cancer … | Apr 2027 |
| Roche | Giredestrant Estrogen receptor alpha degrader | ESR1 | Phase 3 | Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer; Early Breast Cancer; Breast Cancer | Jun 2027 |
| Roche | Giredestrant Estrogen receptor alpha degrader | ESR1 | Phase 3 | Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer; Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer; Locally Advanced or Metastatic Breast Cancer; Early Breast Cancer … | Jul 2027 |
| Sarah Wozney | Conjugated Estrogens CSD Estrogen receptor agonist | ESR1, ESR2 | Phase 3 | Pelvic Organ Prolapse (POP) | Sep 2027 |
| Olema Pharmaceuticals | Palazestrant (OP-1250) Complete Estrogen Receptor Antagonist | ESR1 | Phase 3 | Breast Cancer; Metastatic Breast Cancer | Dec 2027 |
| Jiangsu Simcere Pharmaceutical | [14C] SIM0270 Selective estrogen receptor degrader (SERD) | ESR1 | Phase 3 | Locally Advanced or Metastatic Breast Cancer; Breast Cancer; Healthy Participants; Healthy Adult Participants | Aug 2028 |
| Assistance Publique - Hôpitaux de Paris | Estrogens (ESTREVA® 0.1% gel or PROVAMES® 1 mg) Estrogen receptor agonist | ESR1, ESR2 | Phase 3 | Gender Dysphoria | Jun 2029 |
| University of Virginia | Tamoxifen Estrogen receptor alpha modulator | ESR1 | Phase 3 | Breast Cancer Female | Jun 2029 |
| Azienda Ospedaliero-Universitaria Careggi | tamoxifen Estrogen receptor alpha modulator | ESR1 | Phase 3 | Breast Cancer | Mar 2030 |
| NRG Oncology | Tamoxifen Estrogen receptor alpha modulator | ESR1 | Phase 3 | Stage I Breast Cancer | Apr 2031 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Estrogens, Conjugated Estrogen receptor agonist | ESR2, ESR1 | Phase 3 | Premature Ovarian Insufficiency | Dec 2031 |
| Karolinska Institutet | Tamoxifen Estrogen receptor alpha modulator | ESR1 | Phase 3 | Breast Cancer | Aug 2036 |
| Tokyo Women's Medical University | Endocrine therapy plus ovarian function suppression (OFS) Estrogen receptor antagonism with ovarian suppression | ESR1 | Phase 3 | Breast Cancer | Jan 2038 |
| Sana'a University | Clomiphene Estrogen receptor alpha modulator | ESR1 | Phase 3 | Infertility Drugs | – |
| Hatice Tukenmez Kurnaz | Estriol Estrogen receptor modulator | ESR2, ESR1 | Phase 3 | Pelvic Organ Prolapse | – |
| Atossa Therapeutics | (Z)-endoxifen Selective estrogen receptor modulator (SERM) | ESR1 | Phase 2 | Breast Neoplasms | Nov 2026 |
| AHS Cancer Control Alberta | Tamoxifen Estrogen receptor alpha modulator | ESR1 | Phase 2 | Glioblastoma Multiforme | Dec 2026 |
| Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | Raloxifene Estrogen receptor beta modulator; Estrogen receptor modulator | ESR2, ESR1 | Phase 2 | Breast Cancer; BPH (Benign Prostatic Hyperplasia); Brain Tumor | Dec 2026 |
| Novartis | Fulvestrant Estrogen receptor alpha antagonist; Estrogen receptor degrader | ESR1 | Phase 2 | Advanced Breast Cancer; Breast Cancer | Dec 2026 |
| Tianjin Medical University Cancer Institute and Hospital | Toremifene Estrogen receptor modulator | ESR2, ESR1 | Phase 2 | CANCER | Dec 2026 |
| Centre de recherche du Centre hospitalier universitaire de Sherbrooke | 4FMFES-PET Estrogen receptor (ER) imaging tracer; 18F-labeled fluoroestradiol analogue that binds to | ESR1 | Phase 2 | ER+ Breast Cancer | Dec 2026 |
| Azure Biotech | Lasofoxifene Tartrate (AZU-101) Estrogen receptor modulator | ESR2, ESR1 | Phase 2 | Vulvo Vaginal Atrophy (VVA) | Dec 2026 |
| University of Southern California | bazedoxifene / conjugated estrogens Tissue selective estrogen complex (TSEC) | ESR1, ESR2 | Phase 2 | Atherosclerosis | Dec 2026 |
| Roberta Brinton | PhytoSERM Phytoestrogen supplement containing genistein, daidzein, and S-equol | ESR1, ESR2 | Phase 2 | Menopause | Jan 2027 |
| Washington University School of Medicine | Tamoxifen Estrogen receptor alpha modulator | ESR1 | Phase 2 | Breast Cancer | Jan 2027 |
| National Cancer Institute (NCI) | Z-Endoxifen Hydrochloride Estrogen receptor antagonist | ESR1 | Phase 2 | Recurrent Breast Carcinoma; HER2/Neu Positive; Breast Carcinoma In Situ | Feb 2027 |
| Jose Pablo Leone | Tamoxifen Estrogen receptor alpha modulator | ESR1 | Phase 2 | Male Breast Cancer | Apr 2027 |
| National University Hospital, Singapore | 17 beta-Estradiol topical gel Estrogen receptor agonist | ESR1 | Phase 2 | Arthralgia | Apr 2027 |
| UNC Lineberger Comprehensive Cancer Center | tamoxifen Estrogen receptor alpha modulator | ESR1 | Phase 2 | Breast Cancer | Apr 2027 |
| UNC Lineberger Comprehensive Cancer Center | toremifene Estrogen receptor modulator | ESR2, ESR1 | Phase 2 | Breast Cancer | Apr 2027 |
| University of Kansas Medical Center | Bazedoxifene and Conjugated Estrogens Selective estrogen receptor modulator (SERM) plus estrogen hormone replacement therapy | ESR1, ESR2 | Phase 2 | Risk Reduction | Jul 2027 |
| Abramson Cancer Center at Penn Medicine | 18F-Fluoroestradiol Fluorine-18 labeled estrogen analog for PET imaging of estrogen receptor activity | ESR1 | Phase 2 | Uterine Cancer | Aug 2027 |
| National Cancer Institute (NCI) | Acolbifene Hydrochloride Selective estrogen receptor modulator (SERM) | ESR1 | Phase 2 | Breast Atypical Hyperplasia | Aug 2027 |
| Nutrindo Ideais Research Center | OESTROGEL Transdermal estradiol; estrogen receptor agonist | ESR1, ESR2 | Phase 2 | Menopause | Oct 2027 |
| Nutrindo Ideais Research Center | PENTRAVAN Transdermal estradiol delivery system; estrogen receptor agonist | ESR1, ESR2 | Phase 2 | Menopause | Oct 2027 |
| Shanghai Best-Link Bioscience | BL0175 Estrogen receptor downregulator delivered via nano-medicine formulation | ESR1 | Phase 2 | Breast Cancer (Locally Advanced or Metastatic); Breast Cancer | Oct 2027 |
| Institut Cancerologie de l'Ouest | Tamoxifen Estrogen receptor alpha modulator | ESR1 | Phase 2 | Breast Cancer; Ductal Carcinoma in Situ | Jan 2028 |
| University of Utah | Clomiphene Citrate Estrogen receptor alpha modulator | ESR1 | Phase 2 | Rotator Cuff Tears | Jul 2028 |
| Rutgers, The State University of New Jersey | Tamoxifen Estrogen receptor alpha modulator | ESR1 | Phase 2 | High Risk for Invasive Breast Cancer | Jul 2028 |
| Medical College of Wisconsin | Tamoxifen Estrogen receptor alpha modulator | ESR1 | Phase 2 | Breast Cancer | Sep 2028 |
| QuantumLeap Healthcare Collaborative | Z-endoxifen Estrogen receptor antagonist (active metabolite of tamoxifen) | ESR1 | Phase 2 | Ductal Carcinoma in Situ | Nov 2028 |
| Roswell Park Cancer Institute | Tamoxifen Estrogen receptor alpha modulator | ESR1 | Phase 2 | Anatomic Stage III Breast Cancer AJCC v8 | Nov 2028 |
| Seoul National University Hospital | Tamoxifen Estrogen receptor alpha modulator | ESR1 | Phase 2 | Premenopausal Breast Cancer | Dec 2028 |
| Fred Hutchinson Cancer Center | Transdermal Estrogen Estrogen receptor agonist | ESR1, ESR2 | Phase 2 | Castration-Sensitive Prostate Adenocarcinoma | Jun 2029 |
| Università Vita-Salute San Raffaele | 16-alpha-18F-fluoro-17-beta-estradiol (FES) Radiolabeled estrogen analog binding to estrogen receptor alpha (functionally active ER) | ESR1 | Phase 2 | Breast Cancer Female | Jun 2029 |
| Pfizer | PF-07850327 / ARV-471 / vepdegestrant PROTAC ER degrader | ESR1 | Phase 2 | Locally Advanced or Metastatic ER+ HER2- Breast Cancer | Aug 2029 |
| University of Virginia | transdermal 17β-E2 with cyclic progestin Estrogen receptor agonist with cyclic progestin | ESR1, ESR2, PGR | Phase 2 | Bone Strength | Dec 2029 |
| Memorial Sloan Kettering Cancer Center | tamoxifen Estrogen receptor alpha modulator | ESR1 | Phase 2 | Breast Cancer | Mar 2030 |
| University Health Network, Toronto | Tamoxifen Estrogen receptor alpha modulator | ESR1 | Phase 2 | Hypogonadism | Oct 2030 |
| University of Washington | F-18 16 Alpha-Fluoroestradiol Estrogen receptor imaging agent | ESR1 | Phase 2 | Estrogen Receptor Positive | Apr 2041 |
| Northwestern University | Afimoxifene Estrogen receptor modulator; Estrogen-related receptor gamma antagonist | ESR2, ESR1, ESRRG | Phase 2 | Cancer Survivor | – |
| City of Hope Medical Center | F-18 16 Alpha-Fluoroestradiol Fluorine-18 labeled estrogen receptor ligand for imaging | ESR1 | Phase 2 | Anatomic Stage IV Breast Cancer AJCC v8 | – |
| Shayna Showalter, MD | tamoxifen Estrogen receptor alpha modulator | ESR1 | Phase 2 | Breast Cancer Female | – |
| H. Lee Moffitt Cancer Center and Research Institute | DC1 native/mutated ESR1 Dendritic cell vaccine targeting native and mutated ESR1 epitopes | ESR1 | Phase 1 | Breast Cancer Metastatic Breast Cancer | Nov 2026 |
| Anthony Joshua, FRACP | Tamoxifen Estrogen receptor alpha modulator | ESR1 | Phase 1 | Ovarian Cancer | Jan 2027 |
| University of Pennsylvania | Estrogens, Conjugated Estrogen receptor agonist | ESR2, ESR1 | Phase 1 | Ischemia Reperfusion Injury | Jan 2027 |
| Tianjin Medical University Cancer Institute and Hospital | endocrine therapy estrogen receptor antagonist or degrader (tamoxifen, aromatase inhibitors, or fulvestrant) | ESR1 | Phase 1 | Breast Cancer | Feb 2027 |
| Corium Innovations | Estradiol Estrogen receptor alpha agonist | ESR1 | Phase 1 | Healthy Female Participants; Menopause; Perimenopause; Infertilities … | May 2027 |
| Herbert Lyerly | ESR1 peptide vaccine ESR1-derived peptide vaccine with Montanide adjuvant and GM-CSF | ESR1 | Phase 1 | Breast Cancer | Aug 2027 |
| University of Nebraska | Tamoxifen Estrogen receptor alpha modulator | ESR1 | Phase 1 | Pancreatic Cyst | Nov 2028 |
| St. Joseph's Healthcare Hamilton | Duavive (conjugated estrogens/bazedoxifene) Estrogen receptor agonist with selective estrogen receptor modulator component | ESR1, ESR2 | Phase 1 | Menopause | – |
| Kashiv BioSciences | KSHN001034 Selective estrogen receptor degrader (SERD); fulvestrant equivalent | ESR1 | Phase 1 | Healthy Postmenopausal Women | – |
| University of Oxford | Menopausal hormone therapy (systemic, oestrogen-containing) Oestrogen receptor agonist | ESR1, ESR2 | Phase 1 | Menopause | – |
Breast Cancer (47) Menopause (12) Metastatic Breast Cancer (11) Breast Neoplasms (6) Advanced Breast Cancer (6) Recurrent Urinary Tract Infection (5) Turner Syndrome (4) Breast Cancer Female (3) ER-Positive HER2-Negative Breast Cancer (3) Ductal Carcinoma in Situ (3) Locally Advanced or Metastatic Breast Cancer (3) ER+ Breast Cancer (3)
small molecule (73), mixed (4), other (3), protein or peptide (1)
National Cancer Institute (NCI) (3) Pfizer (3) AstraZeneca (2) University of Southern California (2) Roche (2) Tianjin Medical University Cancer Institute and Hospital (2) University of Virginia (2) Nutrindo Ideais Research Center (2) UNC Lineberger Comprehensive Cancer Center (2) Rutgers, The State University of New Jersey (1) Abramson Cancer Center at Penn Medicine (1) Eurofarma Laboratorios (1) Shayna Showalter, MD (1) Eli Lilly (1) Sarah Wozney (1) Medical College of Wisconsin (1) QuantumLeap Healthcare Collaborative (1) Shanghai Best-Link Bioscience (1) Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair (1) Università Vita-Salute San Raffaele (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.